• PDF / 169,641 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 73 Downloads / 142 Views

DOWNLOAD

REPORT

---

1 S

Hypertriglyceridaemia following off-label use: 2 case reports A report described a 51-year-old man and 45-year-old man, who developed hypertriglyceridaemia following off label treatment with lopinavir/ritonavir and tocilizumab for COVID-19 [routes not stated; not all dosages stated]. A 51-year-old man with stage II chronic kidney disease, was admitted and diagnosed with COVID-19. He started receiving offlabel lopinavir/ritonavir 400mg/100mg twice daily for 14 days on day 10 of hospital admission. On day 9 of the lopinavir/ritonavir treatment, off-label tocilizumab was added. Propofol was briefly administered. His blood serum became lipaemic on day 10 of the lopinavir/ritonavir treatment. Serum triglyceride levels ranged between 921.2–1071.7 mg/dL (hypertriglyceridaemia). Then, he was treated with bezafibrate. Eventually, his lipaemic serum settled. At a follow‐up, no recurrence of lipemic serum was noted. The 45-year-old man, who had a history of hypertension, uncontrolled diabetes mellitus and dyslipidaemia, was admitted and diagnosed with COVID-19. He started receiving off-label lopinavir/ritonavir on day 4 of hospital admission. Subsequently, he started receiving off-label tocilizumab. Propofol was briefly administered. He was also on atorvastatin. However, his blood serum became lipaemic on day 11 of the treatment. Hypertriglyceridaemia was noted. He completed treatment without any further complications. At a follow‐up, no recurrence of lipaemic serum was noted. Rubel AR, et al. Lipemic serum in patients with Coronavirus Disease 2019 (COVID-19) undergoing treatment. Journal of Medical Virology 92: 1810-1811, No. 10, Oct 2020. 803504712 Available from: URL: http://doi.org/10.1002/jmv.25942

0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 3 Oct 2020 No. 1824